Citation

Al Jowf GI, Ahmed ZT, Reijnders RA, de Nijs L, Eijssen LMT. Int. J. Mol. Sci. 2023; 24(6).

Copyright

(Copyright © 2023, Molecular Diversity Preservation International)

DOI

10.3390/ijms24065238

PMID

36982313

PMCID

PMC10049301

Abstract

Post-traumatic stress disorder (PTSD) can become a chronic and severely disabling condition resulting in a reduced quality of life and increased economic burden. The disorder is directly related to exposure to a traumatic event, e.g., a real or threatened injury, death, or sexual assault. Extensive research has been done on the neurobiological alterations underlying the disorder and its related phenotypes, revealing brain circuit disruption, neurotransmitter dysregulation, and hypothalamic-pituitary-adrenal (HPA) axis dysfunction. Psychotherapy remains the first-line treatment option for PTSD given its good efficacy, although pharmacotherapy can also be used as a stand-alone or in combination with psychotherapy. In order to reduce the prevalence and burden of the disorder, multilevel models of prevention have been developed to detect the disorder as early as possible and to reduce morbidity in those with established diseases. Despite the clinical grounds of diagnosis, attention is increasing to the discovery of reliable biomarkers that can predict susceptibility, aid diagnosis, or monitor treatment. Several potential biomarkers have been linked with pathophysiological changes related to PTSD, encouraging further research to identify actionable targets. This review highlights the current literature regarding the pathophysiology, disease development models, treatment modalities, and preventive models from a public health perspective, and discusses the current state of biomarker research.

Language: en

Keywords

Humans; prevention; PTSD; public health; Psychotherapy; stress; treatment; Biomarkers; biomarkers; pathophysiology; Quality of Life; traumatic stress; *Stress Disorders, Post-Traumatic/diagnosis/prevention & control; behaviour changes; Phenotype